Meeting
2019 ASCO Annual Meeting
A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients who have progressed on prior anti-PD-1 therapy.
Authors
Shubham Pant
University of Texas MD Anderson Cancer Center, Houston, TX
Shubham Pant , Imke Mulder , Amishi Yogesh Shah , Pavlos Msaouel , Mehmet Altan , John Weinberg , Alex Stevenson , Funda Meric-Bernstam , Timothy A Yap , Vivek Subbiah , Jordi Rodon Ahnert
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
NCT03637803
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS2670)
DOI
10.1200/JCO.2019.37.15_suppl.TPS2670
Abstract #
TPS2670
Poster Bd #
301a
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Efficacy and safety of pegylated human IL-10 (AM0010) in combination with an anti-PD-1 in renal cell cancer.
First Author: Aung Naing
Poster
2020 ASCO Virtual Scientific Program
Immune activation in first-in-human anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) phase I/II MATINS trial: Part I dose-escalation, safety, and efficacy results.
First Author: Petri Bono
Poster
2019 ASCO Annual Meeting
A phase 1/2a study of GEN-009, a neoantigen vaccine based on autologous peptide immune responses.
First Author: Roger B. Cohen
Poster
2018 ASCO Annual Meeting
Phase I/II study to evaluate the safety and efficacy of tenalisib, a novel PI3K δ/γ dual inhibitor in combination with pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma.
First Author: Rod Ramchandren